如何优化在临床实践中使用抗骨质疏松症药物?
Willem F Lems1, Piet Geusens2,3, Joop van den Bergh4
1Department of Rheumatology, Amsterdam UMC, Amsterdam, Netherlands.
Expert opinion on pharmacotherapy
|December 6, 2025
概括
本综述通过整合FRAX,骨密度和骨折史来优化高骨折风险患者的药物治疗. 它指导了对终身骨折风险管理的药物测序.
科学领域:
- 整形外科 整形外科 整形外科
- 内分泌学 在内分泌学.
- 老年病的医生 老年病的医生
背景情况:
- 药物治疗以减少骨折风险主要针对骨健康.
- 优化药物治疗对于管理高和非常高骨折风险场景至关重要.
研究的目的:
- 在六种常见的临床情况中,为临床医生提供关于优化药物治疗中骨折风险的指导.
- 审查绝经后妇女,葡萄糖皮质类药物使用者和先前骨折的患者的药物治疗策略.
主要方法:
- 对当前治疗骨折风险的药理疗法的叙述性综述.
- 整合FRAX (骨折风险评估工具),骨矿物密度 (aBMD) 和详细的骨折史.
- 考虑基于骨折风险水平的药物测序 (抗吸收剂和骨质合成药).
主要成果:
- 新的数据有助于选择和顺序的抗回收和骨质-合成疗法.
- 建议对终身管理采用治疗到目标的策略.
- 个性化治疗决策是基于综合风险评估.
结论:
- 临床医生可以通过考虑骨折风险水平,病史和骨密度来优化药物治疗.
- 终身跟踪和治疗策略对于管理骨折风险至关重要.
- 综合风险评估指导药理干预措施的选择和排序.
相关概念视频
Drug Dosing: Geriatric Patients
212
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
212
Drug Dosing: Obese Patients
202
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
202
Dosage Regimen Designs: Nomograms and Tabulations
161
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
161
Osteoclasts in Bone Remodeling
3.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Bone Disorders
5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
183
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
183
